<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951050</url>
  </required_header>
  <id_info>
    <org_study_id>D-IC-035</org_study_id>
    <nct_id>NCT04951050</nct_id>
  </id_info>
  <brief_title>Evaluation of the Rapamycin Target Eluting Stent in the Treatment of Coronary Artery Stenosis</brief_title>
  <acronym>TARGET-PREMIER</acronym>
  <official_title>A Prospective, Multicenter, Single-arm Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in Patients With Coronary Artery Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the TARGET PREMIER trail in to demonstrate the safety and efficacy of the&#xD;
      rapamycin target eluting stent in the treatment of subjects with ischemic heart disease&#xD;
      (asymptomatic myocardial ischemia , table or unstable angina), with target lesion(s) in&#xD;
      coronary arteries with visually estimated reference vessel diameter ≥2.25mm and ≤4.0 mm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>9 months</time_frame>
    <description>In-stent late loss at 9 months post-procedure as measured by quantitative coronary angiography (QCA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial ischemia (MI)</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had any MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven TLR</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had Ischemia-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probable and definite stent thrombosis defined by Academic Research Consortium (ARC)</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>percentage of participants that had probable and definite stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss in segment</measure>
    <time_frame>9 months</time_frame>
    <description>Late Lumen Loss in segment at 9 months post-procedure as measured by quantitative coronary angiography (QCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of restenosis ≥50% in-stent or in-segment at 9 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>0 day</time_frame>
    <description>Device Success is defined as a final residual diameter stenosis of &lt;30%, thrombolysis in myocardial infarction (TIMI) 3, by QCA, using the assigned device only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>During the hospital stay to a maximum of the first seven days post index procedure</time_frame>
    <description>Procedure Success defined as achievement of a final diameter stenosis of &lt;30%, TIMI 3, by QCA, using any percutaneous method, without the occurrence of death, Q-wave or non-Q-wave MI, or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion success</measure>
    <time_frame>0 day</time_frame>
    <description>Target lesion success defined as achievement of a final diameter stenosis of &lt;30%, TIMI 3, by QCA, using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>Including ischemia driven or non-ischemia driven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization (TVR)</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>Including ischemia driven or non-ischemia driven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented composite endpoint (PoCE)</measure>
    <time_frame>30days, 6 months, 9months, 12 months and yearly thereafter until 5 years</time_frame>
    <description>defined as all death, all MI and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment %diameter stenosis (%DS)</measure>
    <time_frame>9 months</time_frame>
    <description>In-stent and in-segment %diameter stenosis (%DS) at 9 months post-procedure as measured by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment minimum lumen diameter</measure>
    <time_frame>9 months</time_frame>
    <description>In-stent and in-segment minimum lumen diameter at 9 months post-procedure as measured by QCA.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin target eluting stent</intervention_name>
    <description>Rapamycin target eluting stent</description>
    <arm_group_label>Drug eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Patient with an indication for percutaneous coronary intervention (PCI) including&#xD;
             silent ischemia (in absence of symptoms a positive functional study or a reversible&#xD;
             change in the ECG consistent with ischemia), angina (stable or unstable).&#xD;
&#xD;
          3. Subject acceptable candidate for coronary artery bypass surgery (CABG).&#xD;
&#xD;
          4. Patient or legal guardian is willing and able to provide informed written consent and&#xD;
             comply with follow-up visits and testing schedule.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Treatment up to two target lesions with a maximum of two lesions per epicardial&#xD;
             vessel. If there are two target lesions within the same epicardial vessel, the two&#xD;
             target lesions must be at least 10mm apart per visual estimation.&#xD;
&#xD;
          2. Target lesion(s) must be located in a native coronary artery with a visually estimated&#xD;
             diameter stenosis ≥70%, TIMI 1, lesions length ≤36mm. Target vessel must be visually&#xD;
             estimated diameter of ≥2.25mm to ≤4.0mm.&#xD;
&#xD;
          3. Target lesion must be adequately covered with a single stent.&#xD;
&#xD;
          4. Up to two target lesion needed treatment in one target vessel.&#xD;
&#xD;
          5. One non-target lesion is allowed prior to enrollment if successful. It should be&#xD;
             located at the distal end of the target lesion, and be at lease 10mm apart, when both&#xD;
             are in the same epicardial vessel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Acute myocardial infarction with 1 week or enzyme levels (Creatinkinase or Troponin)&#xD;
             demonstrating that either or both enzyme levels have not returned to normal limits at&#xD;
             the time of the procedure.&#xD;
&#xD;
          2. Target vessel (including branches) PCI within 12 months of the baseline procedure.&#xD;
&#xD;
          3. Known congestive heart failure (NYHA III) or left ventricular ejection fraction (LVEF)&#xD;
             &lt;30%&#xD;
&#xD;
          4. Patient has current unstable arrhythmias.&#xD;
&#xD;
          5. Patient has a history of any coronary arteries brachytherapy.&#xD;
&#xD;
          6. Planned surgery within 6 months after index procedure.&#xD;
&#xD;
          7. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, white blood cell (WBC) count&#xD;
             &lt;3,000 cells/mm3.&#xD;
&#xD;
          8. Impaired renal function (serum creatinine &gt;2.0mg/dl) or patient on dialysis.&#xD;
&#xD;
          9. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any&#xD;
             permanent neurologic defect attribute to cerebral vascular accident (CVA).&#xD;
&#xD;
         10. Patient has a history of bleeding diathesis, contraindication to dual antiplatelet&#xD;
             therapy (DAPT).&#xD;
&#xD;
         11. Known allergy to protocol-required concomitant medications such as aspirin, or&#xD;
             clopidogrel, or heparin and the study stent components such as cobalt, nickel,&#xD;
             chromium, rapamycin or similar drugs.&#xD;
&#xD;
         12. Patient is participating in or plans to participate in any other investigational drug&#xD;
             or device clinical trial that has not reached its primary endpoint.&#xD;
&#xD;
         13. Other serious medical illness with life expectancy less than 1 year (e.g. cancer,&#xD;
             congestive heart failure).&#xD;
&#xD;
         14. Patient has immunosuppressive or autoimmune disease, and is receiving or scheduled to&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
         15. A&#xD;
&#xD;
         16. Women who are pregnant or breastfeeding (women of child-bearing potential must have a&#xD;
             negative pregnancy test with on week before treatment.)&#xD;
&#xD;
         17. Women who intend to become pregnant with 12 months after the baseline procedure (women&#xD;
             of child-bearing potential who are sexually active must agree to use a reliable method&#xD;
             of contraception from the time of screening through 12 months after the baseline&#xD;
             procedure).&#xD;
&#xD;
         18. Patient has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant.&#xD;
&#xD;
         19. Patient is receiving or scheduled to receive chemotherapy or radiotherapy with 30 days&#xD;
             before or any time after the baseline procedure.&#xD;
&#xD;
         20. Patient may not be obedient to the clinical investigation plan through the judgment by&#xD;
             investigators.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Left main artery coronary disease.&#xD;
&#xD;
          2. Three-vessel coronary artery disease.&#xD;
&#xD;
          3. Target lesion is located in or supplied by an arterial or venous bypass graft.&#xD;
&#xD;
          4. In-stent restenosis lesions.&#xD;
&#xD;
          5. Patient has additional lesion(s) for which an intervention with 1 year after the index&#xD;
             procedure would be required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

